|
Originally published In Press as doi:10.1074/jbc.M207982200 on October 11, 2002
J. Biol. Chem., Vol. 277, Issue 50, 48816-48826, December 13, 2002
Genetic Selection of Peptide Inhibitors of Human
Immunodeficiency Virus Type 1 Vpr*
Xiao-Jian
Yao ,
Julie
Lemay,
Nicole
Rougeau,
Martin
Clément§,
Steve
Kurtz¶,
Pierre
Belhumeur, and
Éric
A.
Cohen
From the Laboratoire de Rétrovirologie Humaine,
Département de Microbiologie et Immunologie, Faculté de
Médecine, Université de Montréal, Montréal,
Québec H3C 3J7, Canada and ¶ Northwest Neurologic Inc.,
Portland, Oregon 97210
Human immunodeficiency virus 1 (HIV-1) encodes a
gene product, Vpr, that facilitates the nuclear uptake of the viral
pre-integration complex in non-dividing cells and causes infected cells
to arrest in the G2 phase of the cell cycle. Vpr was
also shown to cause mitochondrial dysfunction in human cells and
budding yeasts, an effect that was proposed to lead to growth arrest
and cell killing in budding yeasts and apoptosis in human cells. In
this study, we used a genetic selection in Saccharomyces
cerevisiae to identify hexameric peptides that suppress the
growth arrest phenotype mediated by Vpr. Fifteen selected glutathione
S-transferase (GST)-fused peptides were found to overcome
to different extents Vpr-mediated growth arrest. Amino acid analysis of
the inhibitory peptide sequences revealed the conservation of a
di-tryptophan (diW) motif. DiW-containing GST-peptides interacted with
Vpr in GST pull-down assays, and their level of interaction correlated
with their ability to overcome Vpr-mediated growth arrest. Importantly,
Vpr-binding GST-peptides were also found to alleviate Vpr-mediated
apoptosis and G2 arrest in HIV-1-producing CD4+
T cell lines. Furthermore, they co-localized with Vpr and interfered with its nuclear translocation. Overall, this study defines a class of
diW-containing peptides that inhibit HIV-1 Vpr biological activities
most likely by interacting with Vpr and interfering with critical
protein interactions.
*
This work was supported by grants from the Canadian
Institute of Health Research and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC) network of excellence (to
E. A. C.), the National Science and Engineering Research Council (to
P. B.), and Fonds pour les Chercheurs et l'Aide à la Recherche
(to E. A. C. and P. B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Recipient of a Médecine-Relève 2000 Messenger
Foundation Award from the Faculté de Médecine,
Université de Montréal.
§
Supported by a doctoral scholarship from the Fonds pour les
Chercheurs et l'Aide à la Recherche.
Recipient of the Canada Research Chair in Human Retrovirology.
To whom correspondence should be addressed. Tel.: 514-343-5967; Fax:
514-343-5995; E-mail: eric.cohen@umontreal.ca.
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Chen, E. Le Rouzic, J. A. Kearney, L. M. Mansky, and S. Benichou
Vpr-mediated Incorporation of UNG2 into HIV-1 Particles Is Required to Modulate the Virus Mutation Rate and for Replication in Macrophages
J. Biol. Chem.,
July 2, 2004;
279(27):
28419 - 28425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Zander, M. P. Sherman, U. Tessmer, K. Bruns, V. Wray, A. T. Prechtel, E. Schubert, P. Henklein, J. Luban, J. Neidleman, et al.
Cyclophilin A Interacts with HIV-1 Vpr and Is Required for Its Functional Expression
J. Biol. Chem.,
October 31, 2003;
278(44):
43202 - 43213.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|